A multi-center, Phase 3 study of lonafarnib (LNF) + ritonavir (RTV) and a combination arm of LNF + RTV + pegylated interferon-alfa (PEG IFN-α) in HDV-infected patients

Trial Profile

A multi-center, Phase 3 study of lonafarnib (LNF) + ritonavir (RTV) and a combination arm of LNF + RTV + pegylated interferon-alfa (PEG IFN-α) in HDV-infected patients

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon alfa (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis D
  • Focus Registrational; Therapeutic Use
  • Acronyms D-LIVR
  • Sponsors Eiger BioPharmaceuticals, Inc.
  • Most Recent Events

    • 21 Mar 2018 According to Eiger BioPharmaceuticals media release, the company is currently defining primary and secondary endpoints with the FDA and plans to initiate the trial in 2H 2018.
    • 09 Mar 2018 New trial record
    • 06 Mar 2018 According to Eiger BioPharmaceuticals media release, the Company plans to initiate this trial by the end of the year 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top